Evidence map›Paper›PMID 30954939›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019

Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter and 8 more

7 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 729 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
729citing papers in PubMed, 8 pooled it
60.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04778345 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT to Detect Peritoneal Carcinomatosis in High-Risk Patients With Gastric Cancer: A Prospective, Single-Center, Comparative Study

TypeinterventionalSponsorFujian Medical UniversityRan2021 to 2023Enrolled72ConditionsEnhanced CT, 18F-FDG PET/CT, 68Ga-FAPI PET/CT, Gastric CancerArms68Ga-FAPI PET/CT scan
NCT05034146 narecruitingnot on this mapstarted 2021, after this paper: background citation

The Diagnostic Efficiency of 68Ga-FAPI PET/CT in Malignant Tumors

TypeinterventionalSponsorZhongnan HospitalRan2021 to 2025Enrolled500ConditionsFibroblast Activation Protein Inhibitor, PET/CT, Malignant NeoplasmArms68Ga-FAPI, PET/CT
NCT05172310 phase1recruitingnot on this mapstarted 2021, after this paper: background citation

PET Imaging of Tumors in Pancreas, Bile Ducts, Stomach and Ovaries by a Novel Tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor

TypeinterventionalSponsorKarolinska University HospitalRan2021 to 2029Enrolled410ConditionsPancreatic Neoplasms, Stomach Neoplasms, Bile Duct Neoplasms, Epithelial Ovarian CancerArms68Ga-FAPI-46, PET/CT
NCT05898854 phase2completednot on this mapstarted 2024, after this paper: background citation

[68Ga]Ga-FAPI PET/CT: The Dagnostic Accuracy for Primary Staging and Re-staging After Chemotherapy in Patients With Gastric and Gastro-esophageal Junctional Cancer

TypeinterventionalSponsorAalborg University HospitalRan2024 to 2025Enrolled20ConditionsGastric Cancer, Gastro Esophageal Junctional Cancer, CancerArms68Ga-FAPi-46
NCT05903807 phase2terminatednot on this mapstarted 2023, after this paper: background citation

[68Ga]Ga-FAPI-46 PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients With Ovarian Cancer

TypeinterventionalSponsorAalborg University HospitalRan2023 to 2026Enrolled20ConditionsOvarian CancerArms68Ga-FAPi-46
NCT06252610 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

PET/MRI Evaluation in Patients With Primary Sclerosing Cholangitis Using Intercellular Matrix Radiopharmaceuticals

TypeobservationalSponsorMassachusetts General HospitalRan2026 to 2029Enrolled10ConditionsPSCArmsRadiotracer Injection, Contrast Media, Magnetic Resonance, Imaging
NCT07337850 recruitingnot on this mapstarted 2024, after this paper: background citation

FAP 2: Utility of Gallium-68-Fibroblast Activation Protein Inhibitor (FAPI) PET in Biliary Tract Cancers: A Prospective Study

TypeobservationalSponsorTata Memorial CentreRan2024 to 2026Enrolled60ConditionsGall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)Armsgallium-68-Fibroblast Activation Protein Inhibitor
3 · Its place in the literature

Who cites it

729 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,374 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Head-to-head comparative study of [Frontiers in oncology · 2026
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Diagnostic Performance of Radiolabelled FAPI Versus [International journal of molecular sciences · 2025
    Pooled it
  9. Comparison of [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  10. Covalent FAPI Imaging-Guided Precision Surgery in Patients with Medullary Thyroid Carcinoma: A Phase II Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  11. Article
  12. PET/MR Imaging of the Gastrointestinal Tract.Magnetic resonance imaging clinics of North America · 2026
    Review
  13. Article
  14. Preoperative [European radiology · 2026
    Article
  15. The Role ofMolecular imaging and radionuclide therapy · 2026
    Article
  16. Comparative Performance ofMolecular imaging and radionuclide therapy · 2026
    Article
  17. Article
  18. Clinical performance of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  19. Utilization ofQuantitative imaging in medicine and surgery · 2026
    Article
  20. Article

669 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Commented on by
    2019
5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Clemens KratochwilDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany clemens.kratochwil@med.uni-heidelberg.de.
Paul FlechsigDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Thomas LindnerDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Labidi AbderrahimDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Annette AltmannDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Walter MierDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Sebastian AdebergDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Hendrik RathkeDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Manuel RöhrichDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Hauke WinterTranslational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany.
Peter K PlinkertDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Frederik MarmeDepartment Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Matthias LangDepartment of Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Hans-Ulrich KauczorTranslational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany.
Dirk JägerDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
Jürgen DebusDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Uwe HaberkornDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Frederik L GieselDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Heidelberg University · DEUniversity Hospital Heidelberg · DEGerman Cancer Research Center · DEHeidelberger Institut für Radioonkologie · DENational Center for Tumor Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on

Indexed as

Gallium RadioisotopesPositron Emission Tomography Computed TomographyBiological TransportEndopeptidasesFibroblast Activation Protein AlphaGelatinasesHumansMembrane ProteinsNeoplasm MetastasisNeoplasmsRadioactive TracersSerine EndopeptidasesEndopeptidasesFibroblast Activation Protein AlphaGallium-68Gallium RadioisotopesGelatinasesMembrane ProteinsRadioactive TracersSerine Endopeptidasesbreast cancercolorectal cancerFAPIlung cancerPET/CT

Identifiers

PMID30954939
PMCPMC6581228
OpenAlexW2930582547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.